Aprotinin decreases blood loss and homologous transfusions in patients undergoing major orthopedic surgery

Anesthesiology

Volumn 88, Issue 1, 1998, Pages 50-57

  Capdevila, Xavier ^a,c   Calvet, Yves ^b   Biboulet, Philippe ^a   Biron, Christine ^a   Rubenovitch, Josh ^b   D'Athls, Françoise ^c  

^a Department of Anesthesiology ^*

^b Laboratory of Hematology

^c LAPEYRONIE HOSPITAL   (France)

Author keywords

Antifibrinolytic drugs; Perioperative use; Sepsis

Indexed keywords

ANTIFIBRINOLYTIC AGENT; APROTININ;

ADULT; ARTICLE; BLEEDING; BLOOD TRANSFUSION; CLINICAL ARTICLE; FEMALE; FIBRINOLYSIS; HEMATOCRIT; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; ORTHOPEDIC SURGERY; PARTIAL THROMBOPLASTIN TIME; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; SEPSIS; THROMBOCYTE COUNT; VASCULAR SURGERY; VEIN THROMBOSIS;

ADULT; AGED; APROTININ; BLOOD TRANSFUSION; DOUBLE-BLIND METHOD; FEMALE; HEMOSTATICS; HUMANS; MALE; MIDDLE AGED; ORTHOPEDIC PROCEDURES; POSTOPERATIVE HEMORRHAGE;

EID: 0031973053     PISSN: 00033022     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000542-199801000-00010     Document Type: Article

References (36)

1. Levy JH, Pifarre R, Schaff UV, Horrow J, Albus R, Spciss B, Rodengart TK, Murray J, Clark RE, Smitli P, Nadel A, Bonney LS, Klcinfield R, A multicenter, double-blind, placebo controlled trial of aprotinin for reducing blood loss and the requirement for donorblood transfusion in patients undergoing repeat coronary artery bypass grafting. Circulation 1995; 92:2236-44
2. Dietrich W, Spannagl M, Jochum M, Wendt P, Schramm \V, Barankay A, Sebening F, Richter JA, Influence of high dose aprotinin treatment on blood loss and coagulation patems in patient undergoing myocardial revascularisation. ANESTIIESIOLOGY 1990; 73:1119-26
3. Royston D, Aprotinin in open heart surgery. Background and results in patients having aortocoronary bypass grafts. Perfusion 1990; 5:63-72
4. Mallet SV, Cos D, Burroughs AD, Rolles K, Aprotinin and reduction of blood loss and transfusion requirements in orthotopic liver transplantation. Lancet 1990; 336:886-7
5. Thompson JF, Roath OS, Francis JL, Webster JHH, Chant ABD, Aprotinin in peripheral vascular surgery. Lancet 1990; 335:911
6. Janssens M, Joris J, David JL, Lemaire R, Lamy M, High dose aprotinin reduces blood loss in patients undergoing total hip replacement. ANESTHESIOLOGY 1994; 80:23-9
7. Murkin JM, Shannon NA, Bourne RB, Rorabeck CH, Cruickshank M, Whyile G, Aprotinin decreases blood loss in patients undergoing revision or bilateral total hip arthroplasty. Anesth Analg 1995; 80:343-8
8. Thorpe CM, Murphy WG, Logan M, Use of aprotinin in knee replacement surgery. BrJ Anaesth 1994; 73:408-10
9. Van Oeveren W, Harden MP, Roozendaal KJ, Elsjman L, Wildevuur CR, Aprotinin protects platelets against the initial effect of cardiopulmonary bypass. J Thorac Cardiovasc Surg 1990; 99:788-97
10. Royston D, High dose aprotinin therapy: a review of the first five year's experience. J Thorac Cardiovasc Surg 1992; 6:76-100
11. Harke H, Gcnnrich T, Aprotinin-ACD-blood: Experimental studies on the effect of aprotinin on the plasmatic and thrombolytic coagulation. Anaesthetist 1980; 29:266-76
12. Grosse H, Lobbes W, Frambach M, Von Broen O, Ringe B, Barthels M, The use of high-dose aprotinin in liver transplantation. The influence on fibrinolysis and blood loss. Thromb Res 1991; 63:287-97
13. Janssens M, Joris J: Is aprotinin worth the risk in total hip replacement [Letter]? ANESTHESIOLOGY 1994; 81:518-9
14. Morrison DC, Ryan JC, Endotoxin and disease mechanisms. Annu Rev Med 1987; 38:417-32
15. Taylor FB Jr, Chang A, Ruf W. Lethal E coli septic shock is prevented by blocking tissue factor with monoclonal antibody. Circ Shock 1991; 33:127-34
16. Bevilacqua MP, PoberJS, Majeau GR, Fiers W, Cotran RS, Gimbrone MA, Recombinant tumor necrosis factor produces procoagulant activity in cultured human vascular endothelium. Proc Natl Acad Sei U S A 1986; 83:4533-47
17. Conway EM, Bach R, Rosenberg RD, Königsberg WH, Tumor necrosis factor enhances expression of tissue factor mRNA in endothelial cells. Thromb Res 1989; 53:234-41
18. Chabbat J, Porte P, Tellier M, Steinbuch M, Aprotinin is a competitive inhibitor of the factor Vila-tissue factor complex. Thromb Res 1993; 71:205-15
19. Murphy WG, Davies MJ, Eduardo A, The haemostatic response to surgery and trauma. BrJ Anaesth 1993; 70:205-13
20. Nyska M, Klin B, Marglies JY, Fasta A, Floman Y, Disseminated intravascular coagulopathy in patients with cancer undergoing operation for pathological fractures of the hip. Int Orthop 1987; 11:1679-81
21. Oison SA, Humphreys WG, Allen WC, DIG complicating Ender's nailing of a pathologic fracture in prostatic carcinoma. A case report. Clin Orthop 1990; 258:242-4
22. Mayer PJ, Gehlsen JA, Coagulopathies associated with major spinal surgery. Clin Orthop 1989; 245:83-8
23. WangsJS, Lin CY, Hung WT, Karp RB, Monitoring of heparininducecl anticoagulation with kaolin-activated clotting time in cardiac surgical patients treated with aprotinin. ANESTIIESIOI.OGY 1992; 77:1080-4
24. Dietrich W, Dilthey G, Spannagl M, Jochum M, Braun SL, Richter JA, Influence of high-Uose aprotinin on anticoagulation, héparine requirement, and celite- and kaolin-activated clotting time in heparinpretreated patients undergoing open-heart surgery. ANESTIIESIOLOGY 1995; 83:679-89
25. Boldt J, Schindler E, Osmer C, Wittstock M, Stermann \VA, Hempedmann G: Influence of different anticoagulation regimens on platelet function during cardiac surgery. lir J Anaesth 1994; 73:639-44
26. LevyJH, Bailey JM, Salmcnpera M, Pharmacokinetics of aprotinin in prcoperative cardiac surgical patients. ANESTIIESIOLOGY 1994; 80:1013-8
27. Haas S, Ketterl R, Stemberger A, Heiss A, The effect of aprotinin on platelet function, blood coagulation and blood lactate level in total hip replacement in a double blind clinical trial. Adv Exp Red Biol 1984; 167:287-97
28. Lu H, Soria C, Cramer EM, Soria J, Mallouf J, Pcrrot JY, Li H, Commin PL, Schumann F, Régnier O, Caen JP, Temperature dé pendance of plasniin-induced activation or inhibition of human platelets. Blood 1991; 77:996-1005
29. Cramer EM, Lu H, Caen JP, Soria C, Berndt MC, Tenza D, Differential redistribution of platelet glycoproteins Ib and Ilb-IIIa after plasmin stimulation. Blood 1991; 77:694-9
30. Quereshi A, Lamont L, Burke P, Grace P, Boucher-Hayes D, Aprotinin: the ideal anticoagulant. Eur J Vase Surg 1992; 6:317-20
31. Espana F, Estelles A, Griffin JII, Aznar J, Gilabert J, Aprotinin (Trasylol) is a competitive inhibitor of activated protein C. Throm Res 1989; 56:751-6
32. Sundt TM, Kouchoukos NT, Saffitz JE, Murphy SF, Wareint TU, Stahl DJ, Renal dysfunction and intravascular coagulation with aprotinin and hypothermie circulatory arrest. Ann Thorac Surg 1993; 55:1418-24
33. Laub G\V, Riebman JB, Chen C, Adkins MS, Anderson WA, Fernandez J, McGrath LB, The impact of aprotinin on coronary artery bypass graft patency. Chest 1994; 106:1370-5
34. Cosgrove DM, Heric B, Lytleb \V, Taylor PC, Novoa R, Golding LA, Stewart R\V, McCarthy PM, Loop FD, Aprotinin therapy for reoperative myocardial revascularization: A placebo controlled study. Ann Thorac Surg 1992; 54:1031-8
35. Lemmer JH Jr, Stanford \V, Bonncy SC, Breen JF, Chomka EV, Eldredge WJ, Holt \VW, Karp RB, Laub GW, Lipton MJ, Aprotinin for coronary bypass operations: efficacy, safety, and influence on early saphenous vein graft patency. A multiccnter, randomized, doubleblind, placebo-controlled study. J Thorac Cardiovasc Surg 1994; 107:543-53
36. Bidstrup BP, Underwood SR, Spasford RN, Streets EM, Effect of aprotinin (Trasylol) on aorto-coronary bypass graft patency. J Thorac Cardiovasc Surg 1993; 105:147-53